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Abstract
Porcine production is a primary market in the world economy. Controlling swine diseases in the farm is essential in order to
achieve the sector necessities. Aujeszky’s disease is a viral condition affecting pigs and is endemic in many countries of the
world, causing important economic losses in the swine industry. microRNAs (miRNAs) are non-coding RNAs which
modulates gene expression in animals, plants and viruses. With the aim of understanding miRNA roles during the Aujeszky’s
disease virus [ADV] (also known as suid herpesvirus type 1 [SuHV-1]) infection, the expression profiles of host and viral
miRNAs were determined through deep sequencing in SuHV-1 infected porcine cell line (PK-15) and in an animal
experimental SuHV-1 infection with virulent (NIA-3) and attenuated (Begonia) strains. In the in vivo approach miR-206, miR-
133a, miR-133b and miR-378 presented differential expression between virus strains infection. In the in vitro approach, most
miRNAs were down-regulated in infected groups. miR-92a and miR-92b-3p were up-regulated in Begonia infected samples.
Functional analysis of all this over expressed miRNAs during the infection revealed their association in pathways related to
viral infection processes and immune response. Furthermore, 8 viral miRNAs were detected by stem loop RT-qPCR in both
in vitro and in vivo approaches, presenting a gene regulatory network affecting 59 viral genes. Most described viral miRNAs
were related to Large Latency Transcript (LLT) and to viral transcription activators EP0 and IE180, and also to regulatory
genes regarding their important roles in the host – pathogen interaction during viral infection.
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Introduction
Domestic pig (Sus scrofa domesticus) can be found worldwide
because of their extraordinary importance in the production of red
meat, lard and cured products [1]. Genetic improvement of the
pig has evolved over the years, from selection for productive and
reproductive characters to more recent interest in product quality
and new non-economic factors, like animal health and welfare [2].
In this sense, safeguard farm sanitary conditions and animal
maintenance are of great interest to provide a better quality of
animal life and also a better pork quality and farm performance.
Aujeszky’s disease (AD), also known as pseudorabies, is a disease of
great economic importance, especially for intensive production
systems that concentrate large farms located relatively near from
each other. The etiological agent of the disease is the AD virus
(ADV), also known as suid herpesvirus type 1 (SuHV-1) and
pseudorabies virus (PRV), from the Alphaherpesvirinae subfamily,
genus Varicellovirus. The disease causes significant economic losses
in pig farms, mainly by reducing the litter size, abortions and slow
growth of the animals, as well as restrictions on movements related
to disease control. Young animals develop symptoms of central
nervous infection while growing pigs and adults display respiratory
signs. Pig is the primary host and the main disseminator of the
disease. Moreover, in pigs surviving the acute infection, virus can
develop a latency stage, and, subsequently, act as a reservoir [3]. It
is a notifiable disease by the World Organisation for Animal
Health (OIE).
SuHV-1 has a linear double-stranded DNA genome of about
142 Kb. Its genome has been fully sequenced [4] and comprises
two unique sequences, the 59 long and the 39 short, the last one
flanked by two inverted repeated sequences. The genome encodes
more than 70 proteins [5], and two spliced transcripts are
described: US1 and the Large Latency Transcript (LLT), while a
third (UL15) has a putative splicing [4]. The virus has the
possibility to induce latency in nervous system after an acute
infection circularizing its genome and persisting like an episome
with limited viral gene expression [6]. The molecular bases of
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latency in herpesviruses are still unknown. The control of the
disease has been based on vaccination campaigns with the use of
marker vaccines obtained by deletion of determined genes like TK
and gE.
During last years, microRNAs (miRNAs) have been described
and characterised as small non-coding RNAs involved in post
transcriptional regulation of gene expression in animals, plants and
some DNA viruses. They participate in a wide range of biological
processes acting mainly through down-regulation of target
messenger RNAs (mRNAs) by blocking protein translation or
inducing mRNA degradation [7–13]. In addition, miRNA
expression has also been associated with many different patholog-
ical processes, such as cancer, neurological disorders, inflamma-
tory pathologies, cardiovascular diseases and infectious diseases
[14–19].
Recently, several studies have confirmed the existence of viral
miRNAs [20–22]. They are miRNAs codified by the viral genome,
and mainly, they are described in the herpesvirus family [22–24].
These viral miRNAs work supporting the development of viral
infection by using host miRNA biogenesis system to control the
expression of their own and host genes [25,26]. They can take
advantage of a conserved gene regulatory mechanism within the
host cell and establish a cellular environment conducive to viral
replication [27]. Viral miRNAs act by regulating fundamental
cellular processes in immunity, apoptosis and key steps in the
transition from latent to lytic infection [6,28–30]. In contrast to
viral proteins, miRNAs can regulate host and own gene expression
avoiding protein factors exposed to host antigenic immune
response and, moreover, viruses also have relative little coding
capacity [24,27,31]. Most studied herpesvirus express miRNAs
during latency, even being a restrictive gene expression stage. In
SuHV-1, for instance, the 13 miRNAs described up to date in
miRBase database (v19, August 2012, URL: http://www.mirbase.
org/, [32–34]) are encoded in the large latency transcript (LLT),
the unique transcript expressed during the latency stage which
generates the Latency Associated Transcripts (LAT) [35,36].
However, little is known about the key roles that viral miRNAs can
develop during the virus infection process. The virus is transmitted
primarily through physical contact between pigs by secretions.
First replication takes part in epithelial tissues and entries directly
into the sensory nerve endings in the nasopharynx. The normal
AD incubation period is from 2 to 6 days. There are several
porcine cells used in many scientific studies that allow the
laboratory culture of SuHV-1, such as the cell line derived from
pig kidney PK-15 [3,35] or dendritic cells [36], but there are no
miRNAs studies involving pig tissues infected with SuHV-1.
In order to unravel the role of viral miRNAs during the ADV
infection process, a SuHV-1 experimental infection using Land-
race pigs was performed using two viral strains (NIA-3 and
Begonia). Furthermore, in vitro infections with the same viral
strains were also conducted. Characterisation and functional study
of viral miRNAs are crucial to understand the molecular bases of
herpesvirus pathogeny and, consequently, to develop mechanisms
to fight against the disease and improve pork production.
Materials and Methods
Biological Material and Ethics Statement
Two strains of SuHV-1 were used in the experiment: the NIA-3
virulent strain and the Begonia attenuated strain. Begonia strain is
derived from NIA-3 strain and is used as live attenuated vaccine.
A total of 20 4-week-old Landrace pigs were used in the
experimental infection with both SuHV-1 strains. All animal
procedures were performed in CReSA biosafety level 3 (BSL3)
facilities (Centre de Recerca en Sanitat Animal, Universitat
Auto`noma de Barcelona, Bellaterra, Spain) and were carried out
according to Spanish and European animal experimentation
ethics law and approved by the institutional animal ethics
committee of Universitat Aunto`noma de Barcelona. Porcine
Kidney (PK-15) cell lines were used for in vitro infection also with
NIA-3 and Begonia SuHV-1 strains.
Cell Culture and Animal Infections
PK-15 cell line was used for viral stocks preparation and in vitro
infections. Cells were grown at 37uC and 5% CO2 and maintained
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 5% FCS, 100 ug/ml streptomycin and 100 IU/ml penicillin.
A viral stock with a titre of 107,57 TCID50/mL was prepared in
PK-15 cells for NIA-3 virulent strain and 108,49 TCID50/mL for
Begonia attenuated strain.
PK-15 cell cultures at 65% of confluence were infected with a
MOI of 0.05 with NIA-3 or Begonia strains. PK-15 cells
inoculated with DMEM were maintained as non-infected cells.
Samples were recovered at 12, 24 and 30 hours post infection
(hpi). Cytopathic effect for both viruses was observed at 24 and 30
hours affecting 25 and 90% of the cells, respectively.
In the in vivo experimental infection, 9 animals were intranasally
inoculated with 103 TCID50 NIA-3 virulent strain, 6 with the same
dose of Begonia attenuated strain and 5 animals with PBS as
healthy pigs. At least one animal per group was euthanized at 4, 5
and 6 days post infection (dpi). The remaining animals were
slaughtered at 7 dpi. Olfactory bulb (OB) and trigeminal ganglia
(TG) samples for each animal were collected, immediately snap-
frozen in liquid nitrogen and stored at 280uC until use. All
samples were taken from CReSA BSL3 facilities (Bellaterra, Spain)
under veterinary supervision.
RNA Isolation
Total RNA was isolated using TRIzolH reagent (Invitrogen,
Carlsbad, USA) following the manufacturer’s recommendations,
quantified using ND 1000 NanodropH Spectrophotometer
(Thermo Scientific, Wilmington, USA) and its quality was assessed
on an Agilent 2100 Bioanalyzer using the RNA 6000 Nano kit
(Agilent Technologies, Santa Clara, USA).
Small RNA Library Construction and High Throughput
Sequencing
A total of 21 libraries were performed in order to high
throughput sequence them (Table 1). 9 libraries were from cell
cultures infected with NIA-3, Begonia or mock-infected (control)
cells at 12, 24 and 30 hpi. The remaining 12 libraries belonged to
animal infections. BO and TG tissues were selected from 3 NIA-3
infected animals euthanized at 4, 6 and 7 dpi, 2 Begonia infected
animals sacrificed at 4 and 7 dpi and 1 healthy animal necropsied
at 5 dpi.
Small RNA fraction from each sample was excised and isolated
from denaturing 12.5% polyacrilamide gel electrophoresis (PAGE)
using miSpikeTM (IDTH, Coralville, USA) as internal size marker.
50 mg of total RNA for each sample were loaded on separate gels
to avoid cross-contamination. Gels were stained with GelStarH
Acid Nucleic Gel Stain (Lonza, Basel, Switzerland) for UV
visualization. Excised small RNA fraction were purified using
PerformaH DTR gel filtration cartridges (EdgeBio, Gaithersburg,
USA). Briefly, 39 and 59 linkers from miRCatTM kit (IDT,
Coralville, USA) were ligated at both ends of the small RNAs in
two separated reactions using a T4 RNA ligase without ATP
(Fermentas, Germany) and T4 RNA ligase with ATP (Ambion,
Viral and Host miRNAs in the ADV Infection
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Austin, USA), respectively. Between 39 and 59 primer ligations, the
60 nt RNAs were purified by PAGE to eliminate unligated
products. Then, linked products were used to perform a reverse
transcription reaction using the SuperScriptTM III Reverse
Transcriptase kit (InvitrogenTM, Carlsbad, USA) and the cDNA
obtained was amplified with the Expand High Fidelity System
Table 1. Summary of employed samples in the study.







CC12 In vitro Mock-infected Cell culture 12 hours Yes Yes
CC24 In vitro Mock-infected Cell culture 24 hours Yes Yes
CC30 In vitro Mock-infected Cell culture 30 hours Yes Yes
NIA12 In vitro NIA-3 infected Cell culture 12 hours Yes Yes
NIA24 In vitro NIA-3 infected Cell culture 24 hours Yes Yes
NIA30 In vitro NIA-3 infected Cell culture 30 hours Yes Yes
BEG12 In vitro Begonia infected Cell culture 12 hours Yes Yes
BEG24 In vitro Begonia infected Cell culture 24 hours Yes Yes
BEG30 In vitro Begonia infected Cell culture 30 hours Yes Yes
32BO In vivo Healthy OB 5 days Yes Yes
37BO In vivo NIA-3 infected OB 4 days Yes Yes
41BO In vivo NIA-3 infected OB 6 days Yes Yes
43BO In vivo Begonia infected OB 7 days Yes Yes
45BO In vivo NIA-3 infected OB 7 days Yes Yes
48BO In vivo Begonia infected OB 4 days Yes Yes
32TG In vivo Healthy TG 5 days Yes Yes
37TG In vivo NIA-3 infected TG 4 days Yes No
41TG In vivo NIA-3 infected TG 6 days Yes No
43TG In vivo Begonia infected TG 7 days Yes Yes
45TG In vivo NIA-3 infected TG 7 days Yes Yes
48TG In vivo Begonia infected TG 4 days Yes Yes
31BO In vivo NIA-3 infected OB 7 days No Yes
34BO In vivo NIA-3 infected OB 4 days No Yes
35BO In vivo NIA-3 infected OB 7 days No Yes
38BO In vivo NIA-3 infected OB 5 days No Yes
39BO In vivo NIA-3 infected OB 7 days No Yes
42BO In vivo Begonia infected OB 6 days No Yes
44BO In vivo Begonia infected OB 7 days No Yes
46BO In vivo Begonia infected OB 7 days No Yes
47BO In vivo Begonia infected OB 5 days No Yes
49BO In vivo Healthy OB 7 days No Yes
50BO In vivo Healthy OB 7 days No Yes
31TG In vivo NIA-3 infected TG 7 days No Yes
34TG In vivo NIA-3 infected TG 4 days No Yes
35TG In vivo NIA-3 infected TG 7 days No Yes
36TG In vivo Healthy TG 4 days No Yes
38TG In vivo NIA-3 infected TG 5 days No Yes
39TG In vivo NIA-3 infected TG 7 days No Yes
44TG In vivo Begonia infected TG 7 days No Yes
46TG In vivo Begonia infected TG 7 days No Yes
47TG In vivo Begonia infected TG 5 days No Yes
49TG In vivo Healthy TG 7 days No Yes
1Post Infection. OB: Olfactory bulb, TG: Trigeminal ganglia.
Two last columns indicate which samples were used to create the libraries for sequencing by Ion PGMTM sequencer (n = 21) and which samples were added later in
order to validate viRs through RT-qPCR (n = 40).
doi:10.1371/journal.pone.0086965.t001
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(Roche, Germany). PCRs were done to amplify the cDNA with
primers complementary to 39 and 59 linkers and, in addition, they
included multiplex identifiers at the 59 end (a five nucleotide
sequence tag) to allow differentiation between libraries. The
number of PCR cycles was optimized for each sample, in order to
minimize/avoid saturation, ranging from 21 to 30. Purification
was carried out by using QIAquick PCR Purification Kit
(QiagenH, Germany). Libraries were quantified with QubitTM
fluorometer, Quant-ITTM (InvitrogenTM, Carlsbad, USA), pre-
pared to a 1011 DNA molecules/mL and equimolecular pooled
according to their indexes. Ion Torrent adapters were ligated to
30 ng of pooled DNA and libraries were then amplified with Ion
Torrent primers for 8 cycles, size selected (2% E-Gel Size Select,
Invitrogen), and sequenced in four 314 chips in Ion PGMTM
sequencer (Life Technologies, Carlsbad, USA) following the
manufacturer’s protocol at DNA sequencing facilities at CRAG
(Bellaterra, Spain). Software version for base calling was Torrent-
Suite v2.0.1 (Life Technologies, Carlsbad, USA). Sequencing data
was deposited at European Nucleotide Archive (ENA, http://
www.ebi.ac.uk/ena/) with the accession number E-MTAB-1868.
Sequence Processing Scheme
Primers sequences were trimmed and only those insert
sequences between 15 and 29 nucleotides and with total number
of sequences $3 were kept for further analysis. For porcine
miRNA profiling, sequences were compared to all available
miRNA sequences (miRBase v19) using local Blast. Parameters
were set to 100% identity and up to 4 mismatches allowed at the
end of the sequences to assume variability on 39 and 59 ends [37].
For viral miRNA discovery, sequences were blasted to SuHV-1
genome (NCBI Reference Sequence: NC_006151.1) considering
100% of alignment and identity (perfect match). Sequences
positioned at annotated regions were discarded. Remaining
sequences were clustered taking into account only the position in
the genome. Hence, sequences positioned in the same region were
grouped and the sequence with higher copy number (CN) was
selected as the reference sequence for each cluster. A total of 14
clusters (viRs) were described and considered as putative viral
miRNAs (Table S1). viRs were blasted to viral miRNAs described
in miRBase v19 and compared to the described SuHV-1 miRNAs
up to date [35,36]. Flanking regions (50 nt) of the selected
reference sequences for each cluster were used to predict pre-
miRNA folding structure using MFold software [38] following the
guidelines reported by Ambros et al. [39] for animal miRNAs
(Figure S1). At the end, 8 viRs were selected for RT-qPCR
detection (Table 2).
Differences in host and viral miRNA expression were assessed.
Total number of sequences obtained for each porcine miRNA or
viR was normalised by library size (in counts per thousand) and,
then, averaged by group. Fold changes (FC) between groups were
calculated using normalised data.
RT-qPCR Detection
For RT-qPCR detection, additional samples from animal
infected tissues were added (OB tissue: 5 NIA-3, 4 Begonia and
2 healthy; TG tissue: 5 NIA-3, 3 Begonia and 2 healthy, reaching
a total of 40 samples. Two samples (37TG and 41TG from NIA-3
group) were not available for RT-qPCR detection due to lack of
amount of cDNA. See Table 1). RT reactions were performed in
duplicate using total RNA as previously described by Balcells et al.
[40]. Briefly, 1 mg of total RNA in a final volume of 20 mL
including 2 mL of 10x poly(A) polymerase buffer, 0.1 mM of ATP,
0.1 mM of each dNTP, 1 mM of RT-primer, 200 U of M-MuLV
Reverse Transcriptase (New England Biolabs, USA) and 2,5 U of
poly(A) polimerase (New England Biolabs, USA) was incubated at
42uC for 1 hour and at 95uC for 5 minutes for enzyme
inactivation. Non template controls (NTC), minus RT and minus
poly(A) polymerase controls for each sample were included.
DNA primers for each viR were designed following the
methodology suggested by Balcells et al. [40] (Table S2). qPCR
reactions were performed in duplicate in 20 mL final volume
including 10 mL SYBRH Select Master Mix (Life Technologies,
Carlsbad, USA), 300 nM of each primer and 5 mL of a 1:20
dilution of the cDNA cell cultures or 1:15 dilution of the cDNA
animal infected tissues on an 7900HT Sequence Detection System
(Applied Biosystems, Warrington, UK). Standard curves were
generated by 5 fold serial dilutions of a pool of NIA-3 and Begonia
infected cell cultures cDNAs in order to calculate the qPCR
efficiency. Thermal profile was set as follows: 50uC for 2 min,
95uC for 10 min and 40 cycles at 95uC for 15 sec and 60uC for
60 sec. NTC and minus poly(A) polymerase controls were
included. Melting curve analysis was included at the end of the
qPCR to detect unspecific amplifications. Hsa-miR-93, Hsa-miR-
25, Ssc-miR-106a, Ssc-miR-17-5p, Ssc-miR-26a were used as
reference miRNAs [41,42].
Quantities from each sample were obtained from the calibration
(standard) curve added in each RT-qPCR reaction, and only those
samples classified as quantifiable were used for statistical analyses.
GeNorm v.3.5 software [43] was used to examine the stability of
the reference miRNAs (M,1.5) and to obtain a normalization
factor (NF). The quantity obtained from each miRNA was
normalised by the NF and FCs were calculated in relation to the
lowest normalised value. Finally, FCs were log2 transformed in
order to perform the statistical analyses with the General Linear
Models procedure of the Statistical Package for the Social
Scientists (IBMH SPSSH Statistics 19; IBM Corporation, Armonk,
USA). In vitro expression data were analysed to study the
differences between the infection groups (NIA-3, Begonia and
mock-infected) and time groups (12/24/30 hours) by a two-way
analysis of variance (ANOVA). Significance threshold was set at
a,0.001 due to the unequal sample size and variances. Estimated
marginal means were also calculated using the least significance
difference (LSD) as confidence interval adjustment. The same
strategy was followed in NIA-3 in vivo expression data for the tissue
group (OB, TG) and time groups (4/5/6/7 days).
Target Prediction and Functional Analysis
DIANA - microT v3.0 web server [44,45] was used to identify in
silico potential mRNA targets for the most abundant and the
differentially expressed porcine miRNAs. Porcine genes are not
included in the current version of DIANA - microT v3.0 and
predictions were based on the human mRNA:miRNA interactions
assuming sequence conservation. In silico functional annotation of
putative mRNA target genes for each miRNA were analyzed with
WEB-based Gene Set Analysis Toolkit (WebGestalt, [46]).
Predicted miRNA targets were functionally annotated through
the biological process information supported by Gene Ontology
(GO, [47]) and the pathways in which they were involved were
described by using the Kyoto Encyclopedia of Genes and
Genomes database (KEGG, [48,49]). Over or under represented
functional categories were identified with hypergeometric test
corrected by the multiple test adjustment proposed by Benjamini
& Hochberg [50]. Significant threshold was set at a,0.05.
The miRanda algorithm [51] was utilised to predict putative
targets for viral miRNAs (viRs), using the following parameters: -sc
140 -en 20. Strict alignments were required in the seed region
(G:U wobble is not allowed). Cytoscape 2.8.2 software [52,53] was
used to build the gene regulatory network formed by viral
Viral and Host miRNAs in the ADV Infection
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miRNAs and their target genes from SuHV-1 genome. Most
abundant DE porcine miRNAs in infected samples were also
added to gene regulatory network.
Results
Clinical Signs of Infected Animals
Seven animals inoculated with NIA-3 strain developed clinical
signs, affecting nervous system, and only two animals euthanized
at 4 dpi only presented pyrexia, maybe due to the early time that
were euthanized. Any animal inoculated with Begonia strain
presented clinical signs.
Sequence miRNA Annotation
A total of 21 small RNA libraries (9 from PK-15 cell line
cultures and 12 from in vivo animal infection) were sequenced in a
Ion PGMTM sequencer (Life Technologies). After trimming the
adaptors sequences, inserts ranging from 15 to 29 nt (correspond-
ing to miRNA size) and found more than two times (copy number
(CN).2) were aligned to miRBase database (v19). 435,434 counts
(4,029 unique sequences) could be aligned to miRBase database,
representing a 37% of total counts used in this study (Table 3). In
PK-15 cell line libraries, 229 miRNAs were described, 109 of them
had been already described in pig, 113 were orthologous miRNAs
and 7 were viral miRNAs (6 from SuHV-1 and 1 from Rhesus
Rhadinovirus – RRV). In in vivo animal infection libraries, a total
of 302 miRNAs were described, 150 that had been previously
described in Sus scrofa, 151 were orthologous and only 1 viral
miRNA from SuHV-1 was found. No viral miRNAs were
identified in mock-infected PK-15 cell cultures and in healthy
animals.
Differential Expression Analysis
In vitro infection. Looking for miRNA abundance differ-
ences among groups (NIA-3 infected, Begonia infected and mock-
infected), 138 miRNAs (60%) were more expressed in mock-
infected group and 91 miRNAs (40%) were more expressed in
infected groups. Interestingly, 35 miRNAs were specifically
expressed in infected groups, whereas two miRNAs were only
expressed in mock-infected group.
miRNAs were considered differentially expressed (DE) when
fold change (FC) difference between groups was greater than 5 or
when a miRNA was not expressed in both infected groups or in
mock-infected group. Out of the 229 miRNAs described in the
in vitro profile, 111 (48%) miRNAs were DE; of which, 69 (30%)
were up-regulated in mock-infected group and 42 (18%) over-
expressed in both infected groups (Table S3). Looking at most
abundant miRNAs (CN.100), we observed a clear predominance
of those miRNAs over-expressed in mock-infected group (Table 4),
such as miR-125b-5p, miR-99b-5p and miR-100. The only
miRNA over-expressed in infected groups with CN.100 was the
viral miR-LLT1 (CN = 3,280). On the other hand, comparing
both infected groups, two miRNAs were up-regulated in Begonia
infected group and down-regulated in NIA-3 infected group,
being, consequently, DE between both infected groups: miR-92a
and miR-92b-3p. Interestingly, miR-2887 presented the highest
FC differences between mock-infected and NIA-3 infected groups
(204 fold). Although it was over-expressed in mock-infected group,
it also was DE between NIA-3 and Begonia infected groups, like
miR-4286 and let-7d-3p.
Focusing on the described viral miRNAs, miR-LLT9 (CN = 3)
was only described in NIA-3 infected group. miR-LLT6, miR-
LLT8 and miR-LLT11a were more expressed in NIA-3 infected
group and miR-LLT1 and miR-LLT2 presented more expression
in Begonia infected group. Only miR-LLT2 was DE between
infected groups, although its abundance was only 13 counts. The
viral miRNA from RRV (miR-rR1–5, CN = 415) was more
expressed in mock-infected group, therefore it was not considered
a real SuHV-1 encoded miRNA, but a miRNA expressed in PK-
15 cells.
In vivo infection. In contrast to in vitro approach, miRNA
abundance differences revealed a turnaround in which 211 (70%)
miRNAs were more expressed in infected NIA-3 and Begonia
groups, and the remaining 91 (30%) miRNAs were more
expressed in healthy group. Moreover, 75 miRNAs were
specifically expressed in infected groups, and only two miRNAs
were only expressed in healthy group.
Focusing on those more expressed miRNAs in infected groups
and DE between them, we observed that miR-206 (FC = 648),
miR-133a (FC = 108), miR-133b (FC = 88) and miR-378 (FC = 5)
were more expressed in NIA-3 group (Table S4). On the other
hand, miR-137 (FC =26) and miR-1249 (FC =25) were the most
expressed miRNAs presenting an up-regulation in Begonia
infected group. The only viral miRNA detected (miR-LLT1,
Table 2. Putative viral miRNAs (viRs) selected for RT-qPCR detection.





viR02 prv-miR-LLT1a 97929–97949 TCTCACCCCTGGGTCCGTCGC 21 2,299 CC+IT +
viR04 prv-miR-7-59b 99282–99301 CCGCCCCCGGGGGGTTGATG 20 27 CC +
viR05 new viR 99302–99322 GGGATGGGCGCTCGGGGGTGA 21 7 CC +
viR06 prv-miR-7-39b 99342–99363 ACCACCGTCCCCCTGTCCCTCA 22 6 CC +
viR08 new viR 99843–99862 TCAAACTTCCTCGTGTCCCC 20 57 CC +
viR09 prv-miR-4c, moR8b 100203–100220 CGGAACCGGGTGCAGGCG 18 872 CC+IT +
viR11 prv-miR-8-39b 100267–100287 CAACCCTTCTGGAGCCCTACC 21 569 CC +
viR14 new viR 102016–102040 TTCCGCCCGCTCTCCCACCGCCTTT 25 4 CC +
ahomology in miRBAse v19 (p-value ,0.001).
bdescribed at (Wu 2012).
cdescribed at (Anselmo 2011).
1Genome Position: start-end.
2CC: Cell Culture (In vitro approach); IT: Infected Tissue (In vivo approach).
doi:10.1371/journal.pone.0086965.t002
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CN = 9) were only expressed in NIA-3 infected group, diverging
from its expression in the in vitro approach, where it was more
expressed in Begonia infected group.
Taking into account both approaches, out of 361 total described
miRNAs, 170 miRNAs were present in both in vitro and in vivo
profiles and 191 miRNAs were present only in one profile (59
miRNAs from in vitro approach and 122 miRNAs from in vivo
approach, see Table S5). There were notable differences in the
expression of profile-shared miRNAs. Only 27 miRNAs followed
the same expression profile in both approaches, and 11 of them
where DE in both groups: 4 miRNAs (miR-26b-5p, miR-29b-2-
5p, miR-450b-5p and miR-450c-5p) were only expressed in
infected groups and the remaining 7 miRNAs (let-7b-3p, miR-
193b, miR-345-5p, miR-1306-5p, miR-2779, miR-2898 and miR-
4286) were more expressed in mock-infected or healthy group,
although all of them were expressed at low levels (CN,100) in
both profiles. On the other hand, 35 miRNAs (CN.100) showed
a different expression pattern between in vitro and in vivo
approaches, but only two miRNAs, let-7i-5p and miR-30d-5p,
presented differential expression regarding both approaches. In
both cases, they were up-regulated in mock-infected group in the
in vitro approach, and their expression changed in the in vivo
approach, having a major expression in NIA-3 infected group.
Among the non-profile-shared miRNAs, there were 6 high
expressed miRNAs (CN.1,000 counts): miR-99a-5p (11,178
counts), miR-10a-5p (3,570 counts), miR-133a (1,990 counts),
miR-218b (1,887 counts), miR-9-3p (1,620 counts) and miR-129a
(1,566 counts). All these 6 miRNAs were expressed in the in vivo
profile, except miR-10a-5p which was expressed in the in vitro
profile.
Target Prediction and Functional Analysis of Host
miRNAs
In silico target prediction were performed for those most
abundant and DE porcine miRNAs presenting differential
expression between NIA-3 and Begonia infected groups: miR-
92a and miR-92b-3p from the in vitro approach and miR-206,
miR-133a, miR-133b and miR-378 from the in vivo approach. A
total of 1,629 target genes were identified (Table S6) and
functionally analysed through KEGG pathways database. Signif-
icant related pathways to target genes were found for all miRNAs
except for miR-378. Interestingly, many pathways related to viral
infection process and immune response resulted significant, such
as RIG-I-like receptor signalling pathway, B and T cell receptor
signalling pathways, Fc gamma R-mediated phagocytosis and
chemokine signalling pathway. Furthermore, miRNAs targets
were also involved in more general biological processes, such as
cell cycle, apoptosis, endocytosis, focal adhesion and RNA
transport and degradation. Finally, pathways focused on nervous
system were also described, like axon guidance, neurotrophin
signalling pathway and long-term potentiation.
Table 3. Summary of sequence processing scheme.
PK-15 cell line cultures Animal infection General
Raw reads obtained 705,846 855,701 1,561,547
Trimmed and non empty reads 500,870 694,944 1,195,814
Counts ranging from 15 to 29 nt 490,848 674,538 1,165,386
Counts aligned to miRBase (unique sequences) 212,519 (2,151) 222,915 (2,841) 435,434 (4,029)
miRNA profile 229 302 361
Sus scrofa miRNAs 109 150 193
Orthologous miRNAs 113 151 161
Viral miRNAs 7 1 7
Counts aligned to SuHV-1 genome (unique sequences) 3,948 (47) 31 (5) 3,979 (50)
Putative viral miRNAs (viRs) 14 2 14
doi:10.1371/journal.pone.0086965.t003
Table 4. The most abundant (CN.100) DE miRNAs between
infected groups (NIA and BEG) and mock-infected group (MI)
in the in vitro approach.
miRNA Counts BEG vs. MI NIA vs. MI NIA vs. BEG
miR-92a 5,495 3.37 21.54 25.20
miR-125b-5p 4,896 27.37 28.36 21.13
miR-LLT1 3,280 – – 24.04
miR-99b-5p 2,220 23.48 26.90 21.99
miR-100 1,891 25.47 27.90 21.44
miR-92b-3p 704 2.18 22.62 25.70
miR-2779 512 21.38 25.41 23.91
miR-2887 479 220.24 2203.79 210.07
miR-2904 408 213.18 221.41 21.62
miR-125a-5p 346 28.13 213.31 21.64
miR-5109 294 29.38 218.18 21.94
miR-4286 243 22.60 216.78 26.45
miR-30a-5p 226 27.87 29.07 21.15
let-7b-5p 209 23.64 25.76 21.58
miR-26a-5p 206 25.33 23.84 1.39
miR-339-5p 176 24.97 222.89 24.60
let-7d-3p 171 21.36 28.66 26.38
miR-19b 144 26.97 24.30 1.62
miR-23a-5p 126 211.83 227.63 22.34
let-7i-5p 122 25.40 26.29 21.17
miR-505-5p 117 215.46 225.93 21.68
miR-4454 104 23.32 27.51 22.26
doi:10.1371/journal.pone.0086965.t004
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Viral miRNA Identification and RT-qPCR Detection
Trimmed and non-empty reads ranging from 15 to 29 nt were
also aligned to SuHV-1 genome (NC_006151.1) considering only
100% of alignment and identity. A total of 3,979 counts (50 unique
sequences) yielded a positive match, 3,948 counts (47 unique
sequences) from PK-15 cell line libraries and 31 counts (5 unique
sequences) from in vivo animal infection libraries (Table 3). All
sequences homologous to an annotated region were removed and
the remaining sequences were clustered by the position in the
SuHV-1 genome resulting in 14 putative viral miRNAs. All of
them were identified in cell cultures and only 2 of them could also
be identified in animal infection samples: viR02 (mir-LLT1 in
miRBase v19) and viR09 (Table 2). None of them were found in
mock-infected cell cultures or in healthy animals. From these 14
putative viral miRNAs, viR03, viR07, viR10, viR12 and viR13
were already described at miRBase as miR-LLT2, miR-LLT6,
miR-LLT8, miR-LLT9 and miR-LLT11a, respectively, and,
consequently, were discarded for RT-qPCR detection. viR02
was also described at miRBase but it was maintained to be the
most expressed viral miRNA in the study. viR01, the only putative
viR which was not located at LLT intronic region, did not succeed
at performing their pre-miRNA structure, and was also removed.
Thereafter, 8 viRs remained to confirm their expression (Table 2)
and a detection protocol through RT-qPCR was designed for
them, which were successfully amplified with high RT-qPCR
efficiencies, ranging from 90% to 110%, and standard curves
correlations were at least of 0.98. Ct and Tm values, as well as
amplification and melting curves can be found at supporting
information (Datasets S1–S4).
Out of these 8 identified viRs, 5 of them were already described
in previous studies [35,36] and remaining 3 viRs were new
described putative viRs (Table 2). viR09 was described as miRNA
offset RNA (moRNA) in the Wu study [35] and our study also
confirmed that viR09 was the moRNA originated from miR-
LLT8 (Figure S1). As moRNAs functions remain unknown
[54,55], the described moRNA in this study (viR09) was kept in
the functional analysis, as it was found in a major relative
abundance than its contiguous mature miRNA and it was
favourably detected through RT-qPCR.
All detected viRs were located in the intronic region of the LLT
transcript, such as all previously described viRs. They were
detected in the NIA-3 and Begonia groups from cell cultures and
only presented expression in some samples from NIA-3 group
from in vivo infection (Figure 1). Begonia group from in vivo
infection as well as all mock-infected and healthy animal samples
from in vitro and in vivo infection resulted without expression for all
studied viRs.
Statistical analyses from RT-qPCR in vitro data revealed no
significant expression differences between NIA-3 and Begonia
groups. Referring at time group, there were significant expression
differences (p-value ,.001), being viRs more expressed in those
samples taken at 24 or 30 hpi than those taken at 12 hpi (p-value
,.001), excepting for viR05, which showed more expression in
12 hpi than in 30 hpi, although without significant differences in
any time group.
Regarding NIA-3 in vivo group RT-qPCR data, statistical
analyses only could be performed for viR02, viR06 and viR09.
Results showed differential expression (p-value ,.001) for tissue
group and time group in all three viRs, being more expressed in
olfactory bulb than in trigeminal ganglia. In time group, viRs
presented differential expression in 4, 5, 6 and 7 dpi, presenting
directional increasing from dpi 4 to dpi 6 and an interesting
decrease of their expression at dpi 7.
Gene Regulatory Network Viral miRNAs
miRanda algorithm was used to form the gene interaction
network between the 8 described viRs and the 70 annotated genes
in SuHV-1 genome, including large latency transcript (LLT). It
found 110 significant interactions between 7 viRs and 59 SuHV-1
genes (Figure 2). No interactions could be retrieved for viR11. The
most interacting viRs were viR04, viR14 and viR06 reaching at
48, 20 and 15 gene interactions, respectively. LLT was the gene
associated to more viRs, up to 5: viR02, viR04, viR05, viR06 and
viR14.
To test if porcine miRNAs can regulate viral genes, most
abundant DE porcine miRNAs between viral strains were also
added to the gene interaction network. Thus, miR-92a, miR-92b-
3p, miR-133a, miR-133b, miR-378 and miR-206 generated a
total of 71 significant interactions with 37 SuHV-1 genes (Figure 2).
miR-133a had 33 gene interactions, including LLT and the
regulatory genes EP0, IE180, UL41 and UL48. miR-92a, miR-
92b-3p, miR-133b, and miR-378 also interacted with LLT and
with the regulatory genes IE180, UL41 and UL48. miR-206 was
not associated to any viral gene.
Discussion
This study is the first work that describes the host and pathogen
miRNA expression profile in an in vitro and as well as in vivo
SuHV-1 infection through high throughput sequencing. Regard-
ing the host miRNAome, 193 porcine miRNAs out of a total of
306 annotated miRNAs in miRBase v.19 were described.
Approximately half of all described miRNAs were orthologous,
evidencing that there are still many porcine miRNAs to be
described in order to complete the current annotation of porcine
miRNAs in miRBase.
First conclusion comparing both profiles was that there were
notable differences among described miRNAs and also among
their expression pattern. Looking at those most abundant miRNAs
in each profile (CN.100), only 33% of miRNAs were shared. This
can be expected because our study has been developed with
material of different nature: cell lines derived from kidney and
nervous tissues from an acute infection, helping to perform
different miRNA profiles and, assuming different expression
patterns. Just comparing the PK-15 profile with the kidney profile
from Timoneda et al., previous study [56], the shared miRNAs
were up to 42%, more than in the in vivo profile, showing some
analogy between PK-15 cells and kidney. However, PK-15 cell
lines were chosen because they were a good substrate for the
laboratory culture of SuHV-1, and, on the other hand, OB and
TG tissues were chosen to be the tissues where the virus replicates
at high level and, therefore, they are the election tissues for viral
detection.
Sequenced libraries revealed a different porcine miRNA
expression profile when the SuHV-1 infection was present, and
presented some homology between the two viral strains used in
this study, NIA-3 (virulent strain) and Begonia (attenuated strain).
The change of expression of some porcine miRNAs between
infected and mock-infected or healthy samples reflects that
miRNAs can play key roles during the viral infection process,
where virus can affect cellular miRNA expression profile on their
own benefit. In this sense, many porcine miRNAs were described
to be down-regulated in the infected samples, particularly in the
in vitro infection, such as miR-125b-5p, miR-99b-5p, miR-100 and
miR-2887, suggesting that viral mechanisms can affect host
miRNA expression. For instance, miR-100 has already been
described to be down-regulated in human cytomegalovirus
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infection [57], showing that it could be associated to viral
infection.
Focusing on the in vivo approach, there were miRNAs DE
between virulent and attenuated strains, particularly more
expressed in NIA-3 infected group, like miR-133a (FC = 108),
miR-133b (FC = 88), miR-378 (FC = 5) and miR-206 (FC = 648),
suggesting that they could work activating those pathways related
to the response against the viral infection. Interestingly, it seems
that they could regulate targets that would be involved to immune
response, such as RIG-I-like receptor signalling pathway, respon-
sible for detecting viral pathogens, or also B and T cell receptor
signalling pathways, which are key components for the activation
of adaptive immunity and T lymphocytes, respectively, and ensure
an efficient response of the immune system. They also were related
to Fc gamma R-mediated phagocytosis, which plays an important
role in host-defence mechanisms through the uptake and
destruction of infectious pathogens, and chemokine signalling
pathway, which works on the inflammatory immune response.
miR-206 was previously described to be up-regulated in influenza
A virus experimental infected pigs, and it was reported to interact
with the antimicrobial protein mucin 1 (MUC1), MyD88 involved
in secretion of type I IFN and pro-inflammatory cytokines, and
chemokine CCL2 [58]. miR-133b plays a role in the maturation
on midbrain dopaminergic neurons [59] and could be involved in
the development of nervous system signs showed in NIA infected
animals.
This change in miRNA expression could be explained by the
differences in both virus strains. Begonia is an attenuated strain
which has been genetically modified, removing glycoprotein E
gene (gE) and thymidine kinase gene (tK), in order to be less
effective at virus replication. In this sense, these miRNAs could
increase their expression when the virulent strain NIA-3 is present
in order to react against infection. It must be taken in
consideration that further investigations to elucidate the biological
roles of these miRNAs are clearly needed, including RT-qPCR
validations, as these results are supported only by high throughput
sequencing data.
Another miRNA which changed its expression pattern between
NIA-3 and Begonia infections was miR-92a. While in the in vitro
samples miR-92a was DE presenting an up-regulation in Begonia
strain infection, in the in vivo samples its expression was higher in
NIA-3 strain infection. A wide range of significant pathways were
associated to miR-92a putative targets, from pathways related to
neuronal functions such as axon guidance, neuro active-ligand
receptor activation and neurotrophin signalling pathway, to
pathways related to more general cellular functions like endocy-
tosis, RNA degradation and focal adhesion. We could argue that
in the in vitro approach, the Begonia strain virus does not receive a
strong defensive response from the host and it could replicate in a
similar level as NIA-3 begonia strain, according to RT-qPCR
results from viral miRNAs expression. In this sense, the host
response generated in the Begonia in vivo infection could cause the
miR-92a fall of expression. Regarding to miR-92b-3p, it
maintained its expression in both approaches, being more
expressed in Begonia strain infection than in NIA-3 strain
infection. As miR-92a, miR-92b-3p target genes were associated
to a wide range of biological processes as well as nervous system
pathways. As its expression has shown invariable in different
Figure 1. Results in viR detection through RT-qPCR for NIA-3 group from in vivo animal infection. Each line represents one sample and
each column describes each studied viR. OB: Olfactory Bulb; TG: Trigeminal Ganglia. Colour determines either the viR could be detected or not in the
sample. Green reflects the detection of the viR in the sample in quantifiable parameters. Yellow defines the detection of the viR without quantifiable
parameters. Red determines that the viR was not detected in the sample. Parameters were considered quantifiable when: (1) viR detection is achieved
in all reactions done per sample (4 RT-qPCR reactions, corresponding to 2 different RT per duplicate) and (2) a minimum of 3 out of the 4 RT-qPCR
reactions have a cycle threshold (Ct) under 35.
doi:10.1371/journal.pone.0086965.g001
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tissues, despite of the viral infection, it could play a more general
cell function.
We observed that the development of the viral infection did not
happen in the same way in cell cultures than in tissues from
experimentally infected pigs. The ability to react and fight against
a viral attack was not the same in in vitro and in vivo due, among
others, to the lack of immune response in cell culture. The miRNA
expression variability can be determined by the frequency of the
most expressed miRNAs in each approach. In the in vitro infection,
miR-23a-3p was the most expressed miRNA representing the 50%
of annotated reads, while miR-125b-5p was the most expressed
miRNA in the in vivo infection, in both olfactory bulb and
trigeminal ganglia, and only represented the 25% of the annotated
reads. Thus, there was a major variability in the animal infection
model. In comparison to previous studies, Anselmo et al. [36]
described miR-21 as the most expressed miRNA in their study by
using dendritic cells as approach, representing almost 91% of all
small RNA sequence tags, while Wu et al. [35] found miR-7f as
the most expressed miRNA in a PK-15 cell line culture, being the
17% of total small RNA reads. As miRNAs expression are spatial
and temporal specific, the disparity of results must be taken in
consideration.
Moreover, miRNAs expression differences in in vitro and in vivo
profiles became more evident by using two different strains of SuHV-
1. In this sense, the two strains were capable of infecting cell cultures
producing cytopathic effect, while in the animals, the attenuated
strain was unable to produce clinical signs showing a less effective
replication, and therefore, we were not able to detect viral miRNAs in
these samples through RT-qPCR. Focusing on viral miRNAs (viRs),
we could detect differences in sequenced data expression between
in vitroand in vivogroups throughmiRBasehomology.Incellcultures,
7 viRs could be detected, being miR-LLT1 (CN = 3,280) the most
Figure 2. Regulatory gene network between SuHV-1 genes and detected viRs and most abundant DE host miRNAs in infected
samples. Node shape represents either is a viral miRNA (hexagon, bright green), a host miRNA (hexagon, dark green) or a viral gene (circular). Node
size simulates the number of interactions, which is directly proportional. Viral gene function is represented by colour: yellow means structural
function (virion envelope, tegument or capside proteins); purple means regulatory function; blue represents viral egress function and grey means
unknown function. LLT transcript is marked in RED and EP0 and IE180 viral activators are marked in orange.
doi:10.1371/journal.pone.0086965.g002
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expressed viral miRNA. In the animal infection, however, only one
viR could be detected in sequenced data, which was also miR-LLT1
(CN = 9). Even so, viral miRNA identification based on genome
sequencehomologyapproachwasable todetectandconfirmthrough
RT-qPCR the expression of 8 putative viRs. It is of great interest
because this study confirms the expression of viral miRNAs
originated from SuHV-1 LLT transcript during lytic infection,
assuming their role in the early stage infection process. Nevertheless,
duetothedifficulties toobtainenoughsmallRNAsespecially fromthe
OB and TG tissues for northern-blot analysis, we describe the eight
novel miRNAs as ‘‘putatives’’.
RT-qPCR expression data showed that there were no significant
differences in viral miRNAs expression between infected groups
(NIA-3 virulent strain and Begonia attenuated strain) in the in vitro
infection, and confirmed that no expression were detected in Begonia
infectedgroupinthe in vivo infection.Asexpected, samples takenat24
and30 hpi in the in vitro infectionpresentedmoreviRexpressionthan
samples taken at 12 hpi. In the in vivo approach, significant
differential expression were described between all 4 times where
samples were taken (4, 5, 6 and 7 dpi), and presented an increasing
expression from day 4 to day 6 and revealing a sudden decrease at day
7. This result could be explained because the expressed miRNAs in
this initialphase of theacute infection inouranimal experimentcould
play a role in the establishment of the infection and can be different
frommiRNAsexpressed ina latentphase,whichcanbethesamethan
whose are found in cell culture, as has been found for other
herpesvirus [60].
Viral gene network analysis deciphered the complex interaction
between the described putative viRs and SuHV-1 genes (Figure 2).
Interestingly, putative viRs were associated with almost all described
SuHV-1 genes [5], as described in a previous study [35]. Large
Latency Transcript (LLT) was the most interacted transcript by viRs,
confirming the important role of them in the latency stage
development. As all previously described viral miRNAs in SuHV-1,
the new putative viRs described in this study were also encoded in the
LLT intronic region, confirming it as the primary and the unique far
miRNA precursor region. In addition, most DE host miRNAs were
also associated to viral regulatory mechanisms, relating the interac-
tion of host miRNAs with the expression of viral genes. The gene
regulatory network deciphered the important role of viR04
presenting up to 24 gene interactions related to structural role, from
proteins related to the virion envelope (glycoproteins) to tegument
and capside proteins. Thus, viR04 may play an important structural
role, although it also presented numerous interactions to genes
involved in processes like DNA repair and recombination, DNA
cleavage, encapsidation and packaging. viR02 and viR14 were
mainly associated to structural genes related to virion envelope
glycoproteins and tegument proteins, and could play important roles
during viral entry and virion morphogenesis. In contrast, viR05 was
associated to non-structural genes related to DNA cleavage and
encapsidationandDNAreplicationandpackaging.Curiously,viR06
presented many interactions with genes related to viral egress (UL3.5,
UL31, UL37 and UL53), which could play an interesting role in the
viral egress process. viR02, viR04, viR06 and viR14 were also linked
to genes associated to regulatory functions (EP0, IE180,UL41,UL48
andUL54). viR09, themoRNAdescribed inthis study,wasassociated
to fewviral genes,whichwereassociated toDNAcleavage, packaging
and replication functions, as well as viral egress and structural role
regarding virion envelope proteins. Regarding the involvement of
host miRNAs in the regulatory network, miR-133a, miR-133b, miR-
92a, miR-92b-3p and miR-378 were related to LLT and the
regulatory genes EP0, IE180, UL41 and UL48. It could mean that
they could play an active role in fighting against the viral infection
process. Moreover, miR-133a was related with many structural and
non structural genes, confirming the importance of miR-133a in the
ADV infection, as it was previously determined to be related with
host-defence pathways.
The potential regulation roles developed by miRNAs not only
in the own host gene machinery but also in the viral infection
mechanisms were described in this study, using in vitro and in vivo
approaches. In addition, this study increases the knowledge about
miRNAs putative functional roles in a herpesvirus infection and
their host-pathogen interactions, supported by an in vivo approach-
ing using nervous tissue.
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